RAFAEL HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
RAFAEL HOLDINGS, INC. (RFL) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$1.44 million for the 3-month period ending 2023-04-30, per its 10-Q filed 2023-06-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2023-06-13
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-04-30 was -$1.44M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-01-31 was -$3.25M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-10-31 was $1.59M.
- RAFAEL HOLDINGS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-04-30 was -$5.53M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2023-04-30 | -$1.44M 10-Q · filed 2023-06-13 | -$4.69M derived: sum of 2 quarters · filed 2023-06-13 | -$3.10M 10-Q · filed 2023-06-13 |
| 2023-01-31 | -$3.25M 10-Q · filed 2023-03-14 | -$1.66M 10-Q · filed 2023-03-14 | |
| 2022-10-31 | $1.59M 10-Q · filed 2022-12-13 | ||
| 2022-04-30 | -$5.53M 10-Q · filed 2023-06-13 | -$7.85M derived: sum of 2 quarters · filed 2023-06-13 | -$119.87M 10-Q · filed 2023-06-13 |
| 2022-01-31 | -$2.32M 10-Q · filed 2023-03-14 | -$114.34M 10-Q · filed 2023-03-14 | |
| 2021-10-31 | -$112.02M 10-Q · filed 2022-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |